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ABSTRACT
Purpose. To evaluate the results of restaging completely
resected stage IIIB/C melanoma prior to start of adjuvant
therapy.
Patients and Methods. One hundred twenty patients with
stage IIIB or IIIC (AJCC 2009) melanoma who underwent
complete surgical resection were screened for inclusion in
our trial investigating adjuvant dendritic cell therapy
(NCT02993315). All patients underwent imaging to
exclude local relapse or metastasis before entering the trial.
The frequency of recurrent disease within 12 weeks after
resection and the method of detection were investigated.
Results. Sixty-nine (58%) stage IIIB and 51 (43%) stage
IIIC melanoma patients were screened. Median age was 54
(range 27–79) years. Twenty-two (18%) of 120 patients
with completely resected stage IIIB/C melanoma had evi-
dence of early recurrent disease, despite exclusion thereof
by prior imaging. Median interval between resection and
detection of relapse was 7.4 (range 4.3–10.7) weeks.
Recurrence was asymptomatic in 17 (77%) patients, but
metastasis was noticed by the patient or physician in 5
(23%). Eight patients with local relapse received local
treatment with curative intent, and one was treated with
systemic therapy. The remaining patients had distant
metastasis, 1 of whom underwent resection of a solitary
liver metastasis while 12 patients received systemic
treatment.
Conclusions. Patients with completely resected stage IIIB/
C melanoma have high risk of early recurrence before start
of adjuvant therapy. Restaging should be considered for
high-risk melanoma patients before start of adjuvant
therapy.
Treatment of stage III melanoma consists of complete
resection with curative intent. However, the risk of recur-
rence afterwards is high, resulting in 5-year overall survival
(OS) rates between 40 and 78%.1–3 Therapeutic options
and prospects for patients with metastatic melanoma have
changed considerably in recent years, especially with the
introduction of immune checkpoint inhibitors and BRAF
and MEK inhibitors.4–10 These drugs have been proven to
significantly improve OS in metastatic melanoma and have
also shown promising results in the adjuvant setting. Phase
III trials investigating adjuvant systemic therapy with
ipilimumab (anti-CTLA-4 antibody) and combined
dabrafenib/trametinib (BRAF/MEK-inhibitor) showed
improved OS compared with placebo.11,12 Adjuvant nivo-
lumab and pembrolizumab (both anti-PD-1 antibodies) led
to improved 12-month recurrence-free survival (RFS) rates
when compared with ipilimumab and placebo, respec-
tively.13,14 Data on OS are still awaited. These results led
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to approval of ipilimumab, pembrolizumab, nivolumab,
and combined dabrafenib/trametinib as adjuvant therapy by
the Food and Drug Administration (FDA). The European
Medicines Agency (EMA) approved use of nivolumab and
combined dabrafenib/trametinib in the adjuvant setting and
received a positive advice from the Committee for
Medicinal Products for Human Use (CMHP) for adjuvant
use of pembrolizumab.15–23
After diagnosis of nodal metastasis in high-risk stage III
melanoma, imaging techniques [e.g. computed tomography
(CT) or 18F-fluorodeoxyglucose (18F-FDG) positron emis-
sion tomography (PET)] are used to exclude distant
metastasis. In stage IIIB/C melanoma, most recurrences
appear within the first 2 years after surgical resection.1
Despite this high risk, incorporation of imaging techniques
in follow-up after resection differs widely between centers.
No survival benefit of imaging during follow-up was
demonstrated in a randomized trial, but this was carried out
prior to the introduction of effective therapies for meta-
static melanoma.24,25 In a clinical trial investigating
adjuvant therapy, it is mandatory to exclude recurrent
disease prior to inclusion, preventing metastatic melanoma
patients from entering the adjuvant study.
We report herein imaging results for 120 stage IIIB and
IIIC melanoma patients who underwent complete surgical
resection within 12 weeks prior to inclusion in a placebo-
controlled, randomized trial investigating adjuvant den-
dritic cell therapy (NCT02993315). Imaging with contrast-
enhanced venous-phase CT (ceCT) or 18F-FDG PET/CT




After signing informed consent, patients were screened
for eligibility in a placebo-controlled randomized trial
(NCT02993315) investigating adjuvant dendritic cell vac-
cination. The protocol has been approved by the national
review committee (Central Committee on Research
Involving Human Subjects) and is in concordance with the
Declaration of Helsinki and Good Clinical Practice. Eli-
gible patients were adults with stage IIIB or IIIC
[American Joint Committee on Cancer (AJCC) 7th edi-
tion]2 cutaneous melanoma within 12 weeks after complete
radical lymph node dissection (RLND) and after recovery
from the surgery. The protocol was amended after publi-
cation of the MSLT-II trial results, which showed no
survival benefit of completion lymph node dissection after
removal of microscopic metastasis with sentinel node
biopsy (SNB) when compared with nodal surveillance.26
After amendment, patients with microscopic disease could
be included after SNB and additional completion lymph
node dissection was no longer required. Macrometastasis
was defined as a palpable node or as a nonpalpable node of
at least 15 mm in short axis on CT, a PET-positive node, or
one or more foci of melanoma of at least 1 cm in diameter
in the pathology report. Patients with completely resected
in-transit and/or satellite metastasis, an unknown primary
tumor, and (planned) adjuvant radiotherapy could be
included. In addition, absence of distant metastasis had to
be documented by ceCT of the chest, abdomen, and pelvis
or whole-body 18F-FDG PET scan combined with CT (18F-
FDG PET/CT) within 6 weeks before inclusion in our trial.
In patients with head or neck melanoma, additional ceCT
of the neck was obligatory. Imaging of the brain was per-
formed in case of clinical suspicion of brain metastasis.
Exclusion criteria included autoimmune disease (except for
skin disease, hypothyroidism after autoimmune thyroiditis,
and type 1 diabetes mellitus), a second malignancy in the
last 5 years (except for adequately treated carcinoma in situ
and basal or squamous cell carcinoma of the skin), con-
comitant use of oral or intravenous immunosuppressive
drugs, and uncontrolled infectious disease.
METHODS
Within 6 weeks prior to the start of the study, imaging to
exclude relapse was performed. Recurrence was considered
symptomatic if suspected by symptoms and/or abnormali-
ties during physical examination. Otherwise, recurrence
was considered asymptomatic. Blood tests, including lac-
tate dehydrogenase (LDH), were carried out within
4 weeks before inclusion. For baseline characteristics, a
conglomerate of lymph nodes with at least four metastatic
lymph nodes and presence of extracapsular extension was
regarded as N3 disease. In case of a conglomerate, the
diameter of lymph node involvement was counted as the
diameter of the conglomerate.
RESULTS
Patient Characteristics
Between November 2016 and July 2018, 120 patients
were screened for eligibility. Baseline characteristics are
presented in Table 1. Median age was 54 (range 27–79)
years, and 76 (63%) of patients were male. Sixty-nine
(58%) and 51 (43%) patients were diagnosed with stage
IIIB and IIIC melanoma, respectively. Twenty-one (18%)
patients had completely resected in-transit metastasis, and
nine (8%) patients presented with nodal metastasis from an
unknown primary tumor. Baseline characteristics of
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during screening (n = 98)
Recurrent disease
during screening (n = 22)
Median (range) age (years) 54 (27–79) 55 (27–79) 51 (27–73)
Sex, n (%)
Male 76 (63) 59 (60) 17 (77)
Female 44 (37) 39 (40) 5 (23)
Stage at screening (AJCC 7th edition), n (%)
IIIB 69 (58) 58 (59) 11 (50)
IIIC 51 (43) 40 (41) 11 (50)
Breslow, n (%)a
\ 2 mm 49 (44) 42 (47) 7 (32)
2–4 mm 24 (22) 19 (21) 5 (23)
C 4 mm 36 (32) 27 (30) 9 (41)
Otherb 2 (2) 1 (1) 1 (5)
Ulceration, n (%)a
Yes 38 (32) 31 (32) 7 (32)
No 73 (61) 58 (59) 15 (68)
Histological type, n (%)a
Superficial spreading melanoma 73 (66) 61 (69) 12 (55)
Nodular melanoma 26 (23) 20 (22) 6 (27)
Other 7 (6) 5 (6) 2 (9)
Missing 5 (5) 3 (3) 2 (9)
Primary site, n (%)
Head/neck 17 (14) 13 (13) 4 (18)
Trunk 46 (38) 37 (38) 9 (41)
Upper extremity 13 (11) 12 (12) 1 (5)
Lower extremity 34 (28) 26 (27) 8 (36)
Genital 1 (1) 1 (1) 0 (0)
Unknown primary 9 (8) 9 (9) 0 (0)
Type of lymph node involvement, n (%)
Microscopic 21 (18) 19 (19) 2 (9)
Macroscopic 99 (83) 79 (81) 20 (91)
Median (range) maximum diameter of lymph node metastasis (cm) 2.0 (0.01–7.5) 1.9 (0.01–7.5) 3.0 (0.25–7.0)
Number of metastatic lymph nodes, n (%)
0 1 (1) 1 (1) 0 (0)
1 46 (38) 40 (41) 6 (27)
2–3 37 (31) 29 (30) 8 (36)
C 4 36 (30) 28 (29) 8 (36)
Site of nodal metastasis
Neck 26 (22) 21 (21) 5 (23)
Axilla 51 (43) 46 (47) 5 (23)
Groin 42 (35) 30 (31) 12 (55)
Popliteal 1 (1) 1 (1) 0 (0)
Extracapsular extension, n (%)
Yes 30 (25) 23 (23) 7 (32)
No 67 (56) 56 (57) 11 (50)
Missing 23 (19) 19 (19) 4 (18)
Restage Melanoma Prior to Adjuvant Therapy 3947
patients with and without recurrent disease during screen-
ing are presented in Table 1. No statistically significant
differences between groups were present.
Detection of Recurrent Disease
Melanoma metastasis was detected in 22 (18%) of 120
patients (Fig. 1), corresponding to a number needed to
screen of 5.45 to detect one patient with recurrent disease.
Thirteen (59%) patients were identified with distant
metastasis, while in the remaining nine (41%) patients,
metastasis was locoregionally located.
Five (23%) recurrences were found based on symptoms
or physical examination (symptomatic recurrence); in three
patients, in-transit metastasis was noticed by the patient
(n = 1) or physician (n = 2), and another patient discov-
ered a local recurrence at the site of the resected primary





during screening (n = 98)
Recurrent disease
during screening (n = 22)
In-transit or (micro)satellite metastases, n (%)c
Yes 21 (18) 17 (17) 4 (18)
No 99 (83) 81 (83) 18 (82)
BRAF, n (%)
BRAF V600E/V600 K 78 (65) 65 (66) 13 (59)
Wild type 34 (28) 29 (30) 5 (23)
Otherd 3 (3) 2 (2) 1 (5)
Missing 5 (4) 2 (2) 3 (14)
aExcluding nine patients with unknown primary tumor
bPrimary melanoma diagnosed as melanocytic tumor of uncertain malignant potential (MELTUMP) in two patients, confirmed by revision
cIncluding locoregional recurrences
dOne inactivating mutation, one p.Leu485Trp mutation, one p.Thr599Dup mutation
AJCC American Joint Committee on Cancer, BRAF B-Raf proto-oncogene, serine/threonine kinase
120 screened for eligibility
22 recurrent disease
98 no recurrent disease
5 symptomatic 17 asymptomatic
2 locoregional 3 distant ± locoregional 10 distant ± locoregional




7 received local treatment
with curative intent
7 locoregional
FIG. 1 Detection of recurrent disease during screening for eligibility
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locoregional relapse, two showed detectable distant meta-
static disease on ceCT scan. The fifth patient developed
back pain, which was suspicious for bone metastasis and
confirmed by ceCT imaging. Seventeen (77%) relapses
were asymptomatic and initially detected by imaging,
corresponding to a number of asymptomatic patients nee-
ded to screen of 6.76. One of these patients presented with
atypical, very small pulmonary nodules before RLND.
Another patient showed atypical/nonspecific hypodense
liver lesions of maximum 10 mm on preoperative ceCT
scan, and these lesions were identified as liver metastases
during screening ceCT after a 12-week interval. Serum
LDH level was not a sensitive parameter for recurrent
disease, since only 4 (18%) out of 22 relapsed patients had
elevated LDH. All four patients had distant metastasis, and
two of them were asymptomatic.
Imaging Techniques and Intervals
Before referral to our trial, metastasis had been excluded
with 18F-FDG PET/CT (85%) or ceCT (15%) in 115
patients. Of the five patients in whom metastasis had not
been excluded prior to screening, four had resected
micrometastasis in the pathology report and one patient had
macrometastatic disease. However, in all patients present-
ing recurrent disease during screening, distant metastasis
had been excluded on imaging prior to start of screening
for eligibility (Fig. 2). For this group with early relapse,
prior imaging was done using 18F-FDG PET/CT in 20
patients (91%) and ceCT in the remaining 2 patients.
To screen for eligibility, 110 (96%) patients had stan-
dard ceCT. In the remaining five (4%) patients, imaging
was performed by 18F-FDG PET/CT. Relapse during
screening was detected by ceCT in all cases. In five
patients, imaging was not repeated during screening, since
the start of experimental adjuvant therapy was within
6 weeks after prior imaging excluding distant metastasis.
The median interval between imaging during screening
and previous imaging was 10.2 (range 5.7–20.9) weeks in
recurrent patients. The median interval between complete
resection and detection of recurrent disease was 7.4 (range
4.3–10.7) weeks. In patients without recurrent disease,
these intervals were not significantly different, with a
median interval between scans of 11.1 (range 5.6–27.7)
weeks and an interval between resection and imaging of
7.3 (range 4.0–11.0) weeks. Figure 3 shows examples of
patients with asymptomatic recurrent disease.
Treatment of Relapsed Patients
Nine patients showed locoregional metastasis, of whom
eight were referred for surgical resection with curative
intent. One patient had no evidence of disease after adju-
vant radiotherapy, therefore planned surgery was
cancelled. This patient was disease free during 13 months
of follow-up, then relapsed. Of the seven reoperated
patients, six developed recurrent disease. In two of them,
distant metastasis occurred within 1 month after resection
of the recurrent local disease. In four patients, the interval
from resection to recurrent disease was 6, 6, 8, and
18F-FDG PET/CT 20  (91%)
ceCT                      2     (9%)
18F-FDG PET/CT 88  (95%)
ceCT                      5     (5%)
No imaging            5
18F-FDG PET/CT  5     (5%)
ceCT                    88   (95%)
No imaging b          5
18F-FDG PET/CT  0     (0%)




































FIG. 2 Time intervals and imaging techniques used prior to intended
start of adjuvant therapy. Time intervals presented as median (range).
aImaging prior to referral for trial participation was performed
postoperatively after sentinel node biopsy (micrometastatic disease)
in nine patients and in three patients with macrometastatic disease.
bImaging was not repeated during screening for eligibility in five
patients, since the inclusion in the adjuvant trial was within 6 weeks
after prior imaging. ceCT contrast-enhanced venous phase CT; 18F-
FDG PET/CT 18F-fluorodeoxyglucose PET scan combined with CT,
RLND radical lymph node dissection, SNB sentinel node biopsy
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9 months. The last reoperated patient is still recurrence free
after 10 months of follow-up. In the remaining patient,
locoregional recurrence consisted of irresectable in-transit
metastasis, for which treatment with anti-PD-1 antibodies
was initiated.
Of the 13 patients with distant metastasis, first-line
treatment consisted of anti-PD-1 antibodies in three
patients, three patients started with combined immune
checkpoint inhibition, and in six patients treatment with
targeted therapy was initiated. One patient underwent
metastasectomy of a solitary liver metastasis.
DISCUSSION
In 120 patients screened for an adjuvant trial, almost one
out of five patients with completely resected stage IIIB or
IIIC melanoma showed evidence of recurrent disease prior
to start of adjuvant therapy, despite adequate prior imaging.
These relapses were present within 2 months after surgery
and within 3 months after previous staging. The majority
of patients with recurrent disease were asymptomatic, and
all were identified by ceCT scan.
Discovery of recurrent disease before start of adjuvant
therapy improves information about prognosis. A proper
baseline scan prevents incorrectly discarding therapy if
metastasis is visualized at the first follow-up scan but was
already present and detectable before start of therapy. In
addition, evidence of relapse can change therapeutic
management. About one-third of patients with recurrent
disease were referred for additional resection with curative
intent due to locoregional relapse. Furthermore, patients
with rapid relapse with relatively high metastatic load
started treatment with BRAF/MEK inhibitors or combined
anti-CTLA-4/anti-PD-1 antibodies. Therefore, reimaging
FIG. 3 Asymptomatic recurrent melanoma during screening: A
patient with pT4aN1b/stage IIIB melanoma (AJCC 7th edition)2
showed no metastatic disease on 18F-FDG PET/CT prior to radical
lymph node dissection (RLND) (a), but venous-phase contrast-
enhanced CT (ceCT) 10 weeks after RLND and 12 weeks after prior
18F-FDG PET/CT showed liver metastasis (b); A patient with
pT2aN2b IIIB melanoma (AJCC 7th edition) showed no metastatic
disease on ceCT (shown) and 18F-FDG PET/CT (not shown) prior to
RLND (c), but ceCT 5 weeks after RLND and 10 weeks after prior
ceCT revealed multiple liver metastases (d)
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before start of adjuvant therapy leads to a change in ther-
apeutic management in a substantial group of patients and
should be considered in all patients despite prior imaging.
A limitation of this study is that we only evaluated
patients screened for eligibility in our clinical trial, hence a
selection bias might have occurred. Patients with more
unfavorable prognosis and higher risk of recurrence are
more likely to be referred for trial participation than
patients who would be referred for approved adjuvant
treatment. On the other hand, some rapid relapses are
missed in our report due to development of symptomatic
metastasis or due to recurrent disease diagnosed at radio-
therapy planning CT scans before screening for eligibility.
The interval between scans was similar between the groups
with and without relapse, therefore a lead-time bias does
not seem to play a role.
To the best of the authors’ knowledge, this is the first
report about detection of early recurrent disease in resected
stage III melanoma before start of adjuvant therapy.
Studies have been conducted to analyze the discovery of
metastasis by imaging in stage III melanoma patients
during follow-up after resection.27–34 However, these
studies performed imaging during follow-up with a longer
interval after surgery and did not report recurrences in
relation to start of adjuvant therapy. Mostly, the first scan
was conducted 6–12 months after surgery, thus information
about rapid asymptomatic relapses within 12 weeks is
lacking. In line with our protocol, phase III trials investi-
gating adjuvant treatment with anti-CTLA-4 or anti-PD-1
antibodies or BRAF/MEK inhibitors excluded metastasis
with CT postoperatively and within 4–6 weeks prior to
randomization.11–14 The trial investigating adjuvant ipili-
mumab versus nivolumab reported that 24% of screened
resected stage IIIB/C/IV patients no longer met criteria and
were not randomized.13 Exact numbers of screening fail-
ures due to recurrent disease were not mentioned but
probably represent an important portion thereof. In addi-
tion, the contribution of relapse in stage IV melanoma
patients, at higher risk for relapse than stage IIIB/C
patients, is not reported. It would be interesting to analyze
the numbers of recurrent disease during screening in the
larger study cohorts of adjuvant phase III trials.
Taken together, about one-fifth of completely resected
stage IIIB/C melanoma patients had recurrent disease
before start of adjuvant treatment. Because of the impact
on prognosis and therapeutic consequences, restaging all
high-risk patients before start of adjuvant therapy seems
appropriate.
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